Internet Pioneer In...
Health Care: Drugs
Cadence Pharmaceuticals Inc. (CADX: NASDAQ)
$2.74 0.04 | 1.29%
06/04/12 - 03:44 PM ET
Company Income Statement
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Sales | 16.70M | 0.00 | 0.00 | 0.00 |
| Cost of Sales | 10.33M | -1.13M | -756.21K | -794.38K |
| Gross Operating Profit | 6.37M | 1.13M | 756.21K | 794.38K |
| Selling, General, and Administrative Expenses | 81.50M | 39.35M | 24.62M | 16.51M |
| Research & Development | 8.88M | 13.76M | 19.46M | 40.02M |
| Operating Income before D & A (EBITDA) | -84.02M | -51.97M | -43.33M | -55.74M |
| Depreciation & Amortization | 3.65M | 1.13M | 756.21K | 794.38K |
| Interest Income | 136.00K | 106.00K | 181.71K | 1.53M |
| Other Income - Net | -1.07M | -1.50M | -450.96K | -180.24K |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -88.60M | -54.50M | -44.35M | -55.18M |
| Interest Expense | 4.42M | 2.14M | 1.14M | 1.92M |
| Pre-Tax Income | -93.02M | -56.64M | -45.49M | -57.10M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -93.02M | -56.64M | -45.49M | -57.10M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -93.02M | -56.64M | -45.49M | -57.10M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -93.02M | -56.64M | -45.49M | -57.10M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-93.02M | -56.64M | -45.49M | -57.10M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -93.02M | -56.64M | -45.49M | -57.10M |
| Basic EPS from Continuing Ops. | -1.41 | -1.09 | -0.93 | -1.55 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -1.41 | -1.09 | -0.93 | -1.55 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -1.41 | -1.09 | -0.93 | -1.55 |
| Basic Normalized Net Income/Share | -1.41 | -1.09 | -0.93 | -1.55 |
| EPS fr Continuing Ops. | -1.41 | -1.09 | -0.93 | -1.55 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -1.41 | -1.09 | -0.93 | -1.55 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -1.41 | -1.09 | -0.93 | -1.55 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-1.41 | -1.09 | -0.93 | -1.55 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with CADX
- Portfolio NameUser Type
- Contributor8 Stocks Below $10 To Avoid
- Contributor10 Most Shorted Stocks in B...
- ContributorRelative Strength Stocks 09...
- Usergrainey Portfolio 1
- Useryourguess Portfolio 1
- Userlives288
- UserCarl Nicola Portfolio 1
- Userron stewart
Latest CADX Headlines from TheStreet
- 8 Stocks Under $10 to Avoid at All Costs 12.23.11 | 12:12 pm
- Pacira: Exparel Approval Easy, Selling Painkiller Harder Challenge 10.31.11 | 11:10 am
- 5 Stocks Showing Relative Strength in a Weak Market 09.22.11 | 02:09 pm
- Biotech Stock Mailbag: Cadence Pharma 03.11.11 | 07:03 am
- Biotech Sector Weekly Rewind 11.06.10 | 09:11 am
- Cadence CEO Discusses Q3 2010 Results - Earnings Call Transcript 11.05.10 | 02:11 pm
- Cadence: When A Drug Approval Sinks Stock 11.03.10 | 10:11 am
- FDA Ends October With Drug Approvals, Rejection 11.01.10 | 07:11 am
- Biotech Stock Mailbag: Exact Sciences 10.15.10 | 07:10 am
- 21 Drugs Facing FDA Approval Decisions 08.31.10 | 08:08 am
Press Releases for CADX
- Cadence Pharmaceuticals Announces Proposed Public Offering Of Common Stock - PR Newswire 11.08.10 | 06:11 am
Partner Headlines for CADX
- Cadence: Not Altering Sales Projections Or Rating In Aftermath Of Product Recall - Seeking Alpha 02.08.12 | 09:02 am
- Cadence Pharmaceuticals: Good For Patients, Bad For Investors - Seeking Alpha 12.26.11 | 08:12 am
- Wedbush Lowers Cadence PT to $10 from $15 - Benzinga 11.23.11 | 01:11 pm
- Company News for November 18, 2011 - Corporate Summary - Zacks 11.18.11 | 10:11 am
- Options Brief: Cadence Pharmaceuticals - Benzinga 07.15.11 | 01:07 pm
- Cadence: Not Unduly Concerned About ANDA Filing Against Ofirmev - Seeking Alpha 07.05.11 | 09:07 am
- 6 Speculative Biotech Stocks Smart Money Loves - Seeking Alpha 05.23.11 | 09:05 am
- Top 15 Most Undervalued Biotech Stocks By Analyst Target Price - Seeking Alpha 04.08.11 | 03:04 pm
- Future Biotech Superstars - Seeking Alpha 03.30.11 | 09:03 am
- Cadence Pharmaceuticals: A Rising Star - Seeking Alpha 03.13.11 | 09:03 am
